Navigation Links
Most Cancer Treatment Studies Aren't Published, Study Finds
Date:9/15/2008

Concern Raised about 'Cancer Publication Bias'

DURHAM, N.C., Sept. 15 /PRNewswire/ -- Less than 20 percent of registered clinical trials of cancer treatment are eventually published in medical journals, according to a study published online today by the journal "The Oncologist."

(LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

Drs. Scott Ramsey and John Scoggins of University of Washington and Fred Hutchinson Cancer Research Center, Seattle, searched the National Institutes of Health's ClinicalTrials.gov registry to identify 2,028 registered research studies of cancer treatment. Major medical journals now require that all studies considered for publication be registered in a publicly accessible database like ClinicalTrials.gov .

A subsequent search of the National Library of Medicine's PubMed database showed that just 17.6 percent of the trials were eventually published in peer-reviewed medical journals. "We find that less than 1 in 5 completed trials registered since the inception of ClinicalTrials.gov are listed in the registry or PubMed as published manuscripts," Drs. Ramsey and Scoggins write.

The publication rate was particularly low for "industry-sponsored" studies, such as those funded by pharmaceutical companies -- just 5.9 percent, compared to 59 percent for studies sponsored by collaborative research networks.

Of published studies, nearly two-thirds had "positive" results-the study treatment worked as hoped. The remaining one-third had "negative" results -- the outcome was disappointing or did not merit further consideration of the tested treatment.

This finding raises concern about "publication bias" in cancer treatment trials. The researchers suspect that the rate of negative results is much higher in the studies that have gone unpublished. Drs. Ramsey and Scoggins write, "It is likely that many unpublished studies contain important information that could influence future research and present practice policy."

There are several reasons why registered trials may not be published. Some trials may fail to meet recruitment or follow-up goals. If the trial is completed and the results are negative, researchers may feel that negative studies do little to advance scientific understanding, or to enhance their professional reputation. Sponsors may not encourage researchers to publish negative results. For their part, medical journal editors may be less enthusiastic about negative studies.

However, publication of negative studies is important for several reasons -- not only to avoid repeating negative trials, but also for what can be learned from the lack of response. "Unpublished trials may have special importance in oncology, due to the toxicity and/or expense of many therapies," the researchers add. The fact that so much cancer research goes unpublished raises concerns about the completeness of available information on present and future cancer treatments.

A pair of accompanying editorials comment on the underpublication of cancer treatment studies, and suggest some approaches to addressing the problem. Dr. James H. Doroshow of the National Cancer Institute (NCI) reports on efforts to develop a database of administrative and outcomes data for all studies performed at NCI-supported institutions.

Drs. Gregory A. Curt and Bruce A. Chabner, Senior Editor and Editor-in-Chief of "The Oncologist," echo the call for increased NCI involvement in ensuring publication of funded studies. Meanwhile, the editors of "The Oncologist" are considering publication of a new, peer-reviewed, fully searchable venue for cancer treatment studies that would otherwise go unpublished. "There is a need for a new venue for publishing all well-executed trials that fail to meet positive endpoints: 'negative' in a sense, but valuable nonetheless," Dr. Curt comments.

The article entitled "Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology," and the accompanying editorials, to be published in the September issue of "The Oncologist," are freely available online at:

http://www.theoncologist.com/cgi/reprint/theoncologist.2008-0133v1

(article by Drs. Ramsey and Scoggins);

http://www.theoncologist.com/cgi/reprint/theoncologist.2008-0174v1

(editorial by Drs. Curt and Chabner);

http://www.theoncologist.com/cgi/reprint/theoncologist.2008-0168v1

(commentary by Dr. Doroshow).

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 26th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 13th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org.

Contact: Dr. Martin J. Murphy, Executive Editor: 919.402.8750, Martin.Murphy@TheOncologist.com


'/>"/>
SOURCE AlphaMed Press
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has ... ("WRB"), a health care service center company based in ... specializes in relationship management programs for leading pharmaceutical manufacturers ... WRB will join Envoy Health Management, ... for manufacturers, biotech firms, and other service companies. Together, ...
(Date:5/4/2017)... -- Fortuna Fix Inc. (" Fortuna "), a private, clinical-stage ... the need for embryonic and fetal stem cells by using ... Fortuna announced today the launch of its ... MD, PhD; Father Kevin FitzGerald , S.J., PhD; Col. ... James Giordano , PhD. "We are excited and ...
(Date:5/4/2017)...  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is teaming up with Auto ... to lower diabetes healthcare costs in Canada ... is available throughout all provinces and territories in ... for additional savings when shopping for Dario supplies in ...
Breaking Medicine Technology:
(Date:5/24/2017)... Utah (PRWEB) , ... May 24, 2017 , ... ... Sick Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal of ... 2017, at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, LP, ...
(Date:5/24/2017)... ... ... thinking of a visit to San Francisco , fall is a great time to ... , Business Architecture Associates is pleased to offer 5 days of training courses, available to ... for individuals, and as 4-½ day corporate package for up to 3 employees with the ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/24/2017)... ... 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com a ... beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ingredient declarations. ... a result, labels need to deliver simple, transparent and clear messaging. Listed food ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® Diagnostics, Inc., ... announced today it had completed the first phase of building a global distribution ... rest of world (ROW) authorized dealers specializing in polysomnography accessories. The company ...
Breaking Medicine News(10 mins):